TI
CUE icon

Trexquant Investment’s Cue Biopharma CUE Stock Holding History

Trexquant Investment’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,336
Closed -$196K – 1569
2022
Q1 		$196K Buy
+1,336
New +$283K 0.01% 1207
2021
Q3 		– Sell
-1,165
Closed -$407K – 1202
2021
Q2 		$407K Buy
1,165
+321
+38% +$124K 0.03% 586
2021
Q1 		$309K Buy
844
+266
+46% +$109K 0.03% 736
2020
Q4 		$217K Buy
578
+104
+22% +$41.6K 0.02% 854
2020
Q3 		$214K Sell
474
-66
-12% -$38K 0.01% 1054
2020
Q2 		$397K Buy
540
+130
+32% +$94.2K 0.03% 763
2020
Q1 		$174K Buy
+410
New +$199K 0.01% 994

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Trexquant Investment's CUE Position: Q2 2022 in Review

Trexquant Investment sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 1,336 shares — an estimated $196K sold.

Trexquant Investment first reported a position in CUE in Q1 2020 and held it in 7 quarters. The position peaked at $407K in Q2 2021. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

  • Trexquant Investment reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
  • Trexquant Investment sold 1,336 Cue Biopharma shares in Q2 2022, an estimated $196K.
  • Trexquant Investment first reported a position in Cue Biopharma in Q1 2020 and held it in 7 quarters.
  • Trexquant Investment's Cue Biopharma position peaked at $407K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.